Equol

Generic Name
Equol
Brand Names
-
Drug Type
Small Molecule
Chemical Formula
C15H14O3
CAS Number
531-95-3
Unique Ingredient Identifier
2T6D2HPX7Q
Background

Equol has been used in trials studying the treatment of Breast Cancer.

Associated Conditions
-
Associated Therapies
-
Clinical Trials
Related News

Acute Equol Supplementation and Vascular Function in Women With and Without CKD

Phase 2
Recruiting
Conditions
Chronic Kidney Diseases
Interventions
Drug: S-equol
First Posted Date
2023-11-13
Last Posted Date
2024-08-23
Lead Sponsor
University of Colorado, Denver
Target Recruit Count
38
Registration Number
NCT06128278
Locations
๐Ÿ‡บ๐Ÿ‡ธ

University of Colorado Anschutz Medical Campus, Aurora, Colorado, United States

Effect of Equol Supplementation on Arterial Stiffness and Cognition in Healthy Volunteers

First Posted Date
2023-02-23
Last Posted Date
2024-11-08
Lead Sponsor
Akira Sekikawa
Target Recruit Count
372
Registration Number
NCT05741060
Locations
๐Ÿ‡บ๐Ÿ‡ธ

Emory University, Atlanta, Georgia, United States

๐Ÿ‡บ๐Ÿ‡ธ

Wake Forest University Health Sciences, Winston-Salem, North Carolina, United States

๐Ÿ‡บ๐Ÿ‡ธ

University of Pittsburgh, Pittsburgh, Pennsylvania, United States

S-equol in Women With Triple Negative Breast Cancer

Early Phase 1
Completed
Conditions
Breast Cancer
Interventions
Drug: S-equol
First Posted Date
2015-01-30
Last Posted Date
2020-07-22
Lead Sponsor
The University of Texas Health Science Center at San Antonio
Target Recruit Count
39
Registration Number
NCT02352025
Locations
๐Ÿ‡บ๐Ÿ‡ธ

CTRC (Cancer Therapy and Research Center) at UTHSCSA, San Antonio, Texas, United States

Multi-Dose Safety and Pharmacokinetic Study of S-Equol in Healthy Volunteers

Phase 1
Completed
Conditions
Healthy
Interventions
Drug: S-equol
Drug: Placebo
First Posted Date
2009-10-21
Last Posted Date
2012-07-12
Lead Sponsor
Ausio Pharmaceuticals, LLC
Target Recruit Count
41
Registration Number
NCT00998920
Locations
๐Ÿ‡บ๐Ÿ‡ธ

Charles River, Tacoma, Washington, United States

Efficacy and Safety of S-Equol on Men With Benign Prostatic Hyperplasia

Phase 2
Completed
Conditions
Benign Prostatic Hyperplasia
Interventions
Drug: Placebo
Drug: S-equol
First Posted Date
2009-08-20
Last Posted Date
2017-05-19
Lead Sponsor
Ausio Pharmaceuticals, LLC
Target Recruit Count
116
Registration Number
NCT00962390
Locations
๐Ÿ‡ฎ๐Ÿ‡ณ

Indraprastha Apollo Hospital, Delhi, India

๐Ÿ‡ฎ๐Ÿ‡ณ

Samved Hospital, Ahmedabad, India

๐Ÿ‡ฎ๐Ÿ‡ณ

M S Ramaiah Memorial Hospital, Bangalore, India

and more 12 locations

Efficacy and Safety of S-equol on Vasomotor Symptoms in Menopausal Patients

Phase 2
Completed
Conditions
Menopause
Interventions
Drug: Placebo
Drug: S-equol
First Posted Date
2009-08-20
Last Posted Date
2014-04-08
Lead Sponsor
Ausio Pharmaceuticals, LLC
Target Recruit Count
169
Registration Number
NCT00962585
Locations
๐Ÿ‡บ๐Ÿ‡ธ

Greater Cincinnati OB/GYN, Inc., Cincinnati,, Ohio, United States

๐Ÿ‡บ๐Ÿ‡ธ

Radiant Research, Inc, Greenville, South Carolina, United States

๐Ÿ‡ฆ๐Ÿ‡บ

Royal Hospital for Women, Randwick, New South Wales, Australia

and more 6 locations

Safety and Pharmacokinetic Study of S-Equol in Healthy Volunteers

Phase 1
Completed
Conditions
Healthy
Interventions
Drug: Placebo
Drug: S-equol
First Posted Date
2008-11-07
Last Posted Date
2012-01-20
Lead Sponsor
Ausio Pharmaceuticals, LLC
Target Recruit Count
60
Registration Number
NCT00787007
Locations
๐Ÿ‡บ๐Ÿ‡ธ

Charles River, Tacoma, Washington, United States

ยฉ Copyright 2024. All Rights Reserved by MedPath
HomeTerms & ConditionsPrivacy Policy